Insider Selling: Edwards Lifesciences Corp VP Sells 5,000 Shares of Stock (EW)
Edwards Lifesciences Corp (NYSE:EW) VP Patrick B. Verguet unloaded 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $93.00, for a total value of $465,000.00. Following the completion of the transaction, the vice president now directly owns 49,053 shares of the company’s stock, valued at approximately $4,561,929. The sale was disclosed in a legal filing with the SEC, which is available at this link.
A number of analysts have recently weighed in on EW shares. Analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday, July 31st. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $90.00.
Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 1.28% on Wednesday, hitting $95.01. The stock had a trading volume of 1,208,077 shares. Edwards Lifesciences Corp has a 52-week low of $60.62 and a 52-week high of $95.39. The stock’s 50-day moving average is $87.08 and its 200-day moving average is $78.33. The company has a market cap of $10.033 billion and a P/E ratio of 13.54.
Edwards Lifesciences Corp (NYSE:EW) last announced its earnings results on Tuesday, July 29th. The company reported $0.88 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the prior year, the company posted $0.82 earnings per share. The company’s quarterly revenue was up 11.2% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp will post $3.28 EPS for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.